Site Registration
Registration benefits include:
- Access to CME/CE programs
- Free subscription to Current Medical Evidence
- Reminders of new CME/CE activities
About This Site
OsteoporosisTX.com is designed to provide educational resources for clinicians who manage patients who have, or are at risk for osteoporosis. Our goal is to offer our users easily accessible, up-to-date clinical information and to create a community of health care professionals that share clinical insights.
A variety of resources are available, including:
- A wide selection of Continuing Education (CME/CE) activities. CME/CE opportunities include newsletters, Webcasts, On-the-Go Education, and more (free registration required)
- Links to the latest news about osteoporosis and its management
- Exclusive Ask the Expert feature where users can direct questions to our expert panel
- A comprehensive, regularly updated listing of osteoporosis-related clinical trials
- A searchable list of journal articles on osteoporosis research, diagnosis, and treatment
- An extensive directory of meetings and other useful links
Latest News
- RT @ASBMR: The AuSBMR announces it’s 2012 International Research Prize. Learn more: http://t.co/oNyCfkra. #bone #research #grants
- RT @ASBMR: Please share! JBMR seeks next Editor-in-Chief! Interested? Learn more and apply at http://t.co/y7SCBSVO . #asbmr #jobs
Follow us on Twitter!
Current Ask the Expert Question
Long-term bisphosphonate therapy in patients with stable bone mineral density: maintain or discontinue?
Following the recent news on the relationship between long-term bisphosphonate use and atypical fractures, I have had several of my patients who are taking bisphosphonates for osteoporosis ask me about the suitability of continued treatment. What has me a bit perplexed are the patients who have been receiving bisphosphonate therapy for 5 or so years and have had stable bone mineral density (BMD) scores for the last 2+ years. How would you recommend proceeding with these patients? Should they continue with their bisphosphonates or be switched to another agent, or should therapy be discontinued altogether? What is the best way to communicate this decision to the patient?
